JOURNAL OF INVESTIGATIVE DERMATOLOGY皮肤病学研究杂志
JOURNAL OF INVESTIGATIVE DERMATOLOGY(英文缩写 J INVEST DERMATOL),ISSN 0022-202X,eISSN 1523-1747,中文译名:皮肤病学研究杂志 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 7.590 | Q1 |
| 2022 | 6.500 | Q1 |
| 2023 | 5.700 | Q1 |
| 2024 | 5.700 | Q1 |
| 2025 | 7.000 | Q1 |
JOURNAL OF INVESTIGATIVE DERMATOLOGY 最新收录文献
-
1. Part II. Measuring skin pain in humans: Quantitative, psychophysical, and patient-reported tools for dermatology.
PMID:日期:2027-04-07Quantifying skin pain is essential for dermatologic research and patient care. This Methods and Techniques in Skin Research article (part II) synthesizes human-focused tools spanning psychophysical and patient-reported measures. A standardized workflow for quantitative sensory testing (QST) outlines the measurement of thermal detection and pain thresholds, mechanical detection and pinprick pain, temporal summation, dynamic mechanical allodynia, vibration, and pressure; these techniques enable phenotyping of gain and loss of somatosensory function. Core patient-reported outcome measures (PROMs) such as the Numeric Rating Scale, Visual Analog Scale, and multidimensional instruments are summarized alongside disease-specific measures, with emphasis on recall periods, meaningful change thresholds, and adaptations for special populations when available. Disease-focused sections outline nociceptive (eg, atopic dermatitis, wounds), neuropathic (eg, polyneuropathy, postherpetic neuralgia), and mixed (eg, hidradenitis suppurativa) pain profiles, illustrating how pairing QST with PROMs enhances understanding. Objective markers such as evoked potentials, physiologic signals, and molecular biomarkers are reviewed, noting current limitations in standardization and clinical adoption. Future priorities include validation of tools across diseases and populations and the creation of guidelines for QST use in clinical dermatology. Together, these methods provide an actionable framework for harmonizing skin-pain measurement, improving trial comparability, and informing the development of targeted therapies.
-
4. Distinct IL-17A and retinoic acid-associated gene programs are enriched in epithelialized tunnels in severe hidradenitis suppurativa.
4. 在重症化脓性汗腺炎中，独特的IL-17A和维甲酸相关基因程序在上皮化隧道中富集PMID:日期:2026-09-22该文献暂无摘要。
-
7. DNPH1 exerts context-dependent tumor-promoting and -repressing functions during melanoma development.
PMID:日期:2026-09-22Metastatic cutaneous melanoma is a highly lethal and multifarious disease that is driven by the interplay between UV-induced DNA damage and oncogenic lesions, yet enzymes coupling these processes remain incompletely defined. We uncovered the deoxynucleotide hydrolase DNPH1 as an overexpressed melanoma enzyme associated with metastasis and poorer patient survival. DNPH1 overexpression or downregulation in human melanoma cells enhanced or lowered, respectively, their in vitro growth rate. In vivo, Dnph1 loss delayed melanoma initiation and reduced distant metastasis in UV light-exposed, BRAF-V600E-expressing mice. Similarly, Dnph1 knockout in conjunction with oncogenic BRAF-V600E slowed melanoma onset upon ablation of the tumor suppressor TP53. Surprisingly, Dnph1 knockout facilitated growth of tumors after their establishment, indicating stage-specific functions during melanoma development. Mechanistically, UV light triggered the translocation of DNPH1 into the cell nucleus, where it may alter DNA repair pathway choice by suppressing nucleotide excision repair while enhancing homologous recombination and non-homologous end joining. DNPH1 also promoted NF-κB signaling, which may involve cooperation with two interaction partners, ANXA2 and FHL2, in stimulating NF-κB-dependent transcription. Altogether, these findings have identified DNPH1 as a previously unrecognized regulator in the development of cutaneous melanomas where it functions in a context-dependent manner as a tumor promoter or attenuator.
-
9. Skin Cancer Risk Stratification and Outcomes in Swedish Solid Organ Transplant Recipients.
PMID:日期:2026-09-22Solid organ transplant recipients (SOTRs) have an increased risk of cutaneous malignancies due to long-term immunosuppressive therapy. To evaluate a risk stratification model for follow-up of SOTRs at Karolinska University Hospital, Sweden, in which SOTRs are categorized based on skin cancer risk (low, intermediate, high), 395 patients were followed from 2010 until 2023 in this retrospective, real-world cohort. Over a third of SOTRs (n=151, 38.23%) developed invasive skin cancer. High-risk SOTRs (n=30) displayed the shortest time to first post-transplant invasive skin cancer, followed by intermediate- (n=112) and low-risk SOTRs (n=253) (p<0.0001). In adjusted analyses, intermediate- and high-risk SOTRs had 5.98-fold (95% confidence intervals (CI): 4.05-8.34) and 11.90-fold (95% CI: 7.02-20.19) higher hazard of invasive skin cancer compared to low-risk SOTRs, respectively. Intermediate- and high-risk SOTRs had 1.53-fold (95% CI: 1.03-2.27) and 1.97-fold (95% CI: 1.10-3.54) higher hazard of death compared to low-risk SOTRs. Ten patients developed metastasis and four died of skin cancer. This model serves as a dynamic tool for follow-up and provides time-to-skin-cancer discrimination between intermediate- and low-risk SOTRs. The findings illustrate the potential utility of risk-based stratification of SOTR follow-up and secondary prevention of cutaneous malignancies, potentially improving survival outcomes in this patient group.
-
10. Proteomic signature predicts the metastatic risk of primary cutaneous squamous cell carcinomas.
PMID:日期:2026-09-22Cutaneous squamous cell carcinoma (cSCC) is a heterogeneous skin malignancy worldwide. While most tumours are effectively treated by surgical excision, between 5% and 37% of biologically aggressive cases metastasise to regional lymph nodes or distant organs. Identifying tumours at risk of metastasis remains challenging, particularly for the 16-30% of cases lacking clear clinical or histopathological high-risk features. In this study, we applied a mass spectrometry-based proteomic approach to profile archival primary cSCC samples with and without confirmed metastasis. A total of 4,819 protein groups were identified, of which 284 were differentially abundant between the groups. The differential abundance of a subset of proteins was further validated in silico using independent transcriptomic datasets. These proteins were enriched in pathways associated with metastatic hallmarks, including reduced apoptosis, decreased cell adhesion and differentiation, and increased angiogenesis and keratinocyte migration. Classification analysis using support vector machine models achieved 88.66% accuracy in predicting metastatic potential. Collectively, these findings demonstrate the potential of proteomics to improve metastatic risk stratification and guide clinical management of cSCC, ultimately supporting better patient outcomes.